到 2028 年经皮中枢神经系统 (CNS) 治疗市场

这份报告考察了透皮中枢神经系统 (CNS) 治疗市场，提供了市场概述、技术趋势、需求驱动因素、按细分市场划分的药物趋势以及进入市场的公司概况。我正在整理。

内容

• 执行摘要
• 到 2028 年将出现经皮中枢神经系统药物
• 市场机会
• 透皮给药动力学
• 需求驱动因素
• 贴片製造动态
• 离型纸
• 背衬膜
• 半透膜
• 粘合剂
• 透皮中枢神经系统药物市场
• 多动症
• 戴特拉纳
• □甲酯（Daytrana - 诺文）
• 阿尔茨海默病
• 卡巴拉汀（Exelon - 诺华）
• Aricept 透皮吸收剂 - 近期活动
• 艾克赛隆
• 抑郁症
• 抗抑郁药
• 司来吉兰（EMSAM - 迈兰）
• 噁心
• 生物碱
• 东莨菪碱 (Transderm Scop) 葛兰素史克消费者健康
• 格拉司琼（Sancuso - ProStrakan）
• 帕金森病
• 左旋多巴
• 罗替戈汀（Neupro - Schwarz/UCB））
• 精神分裂症
• 阿塞那平（Secuado - 诺文）
• 透皮中枢神经系统药物分析及市场评价
• FDA 批准的透皮中枢神经系统处方产品
• 中枢神经系统兴奋剂
• 乙□胆碱酯□抑製剂
• 非典型抗精神病药
• 生物碱
• 多巴胺激动剂
• 5-HT3受体拮抗剂
• MAO抑製剂
• 战略因素和品牌问题
• 多巴胺激动剂
• 公司简介

“Transdermal CNS Therapeutics to 2028: Products, Therapeutics, Markets and Forecasts” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector. The study is designed to provide drug company decision makers, drug delivery developers, patch designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for Transdermal patches Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Converging Factors Driving Growth in Transdermal Delivery

Transdermal CNS drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic materials and patch design have led to patches that are more esthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package. Growth in demand for drug patches is being driven by several factors - factors with strong demographic and population trend underpinnings. Further improvements to transdermal transport and the introduction of new patch designs will keep this segment expanding through 2028.

What You Will Learn:

• Analyzes and evaluates current transdermal CNS therapeutics markets and products and assesses the market potential for existing and probable future products

• Analyzes patch designs, technologies and patch development issues

• Profiles patch manufacturers and third-party transdermal supply chain companies

• Provides detailed assessments of more than a dozen products in more than a dozen product categories

• Provides market data and forecasts to 2028

• Profiles transdermal drug patch product providers, their product development activity, and strategies

• Evaluates the impact of economic, technology, and regulatory factors

Table of Contents

• Executive Summary
• Transdermal CNS Therapeutics to 2028
• The Market Opportunity
• Transdermal Drug Delivery Dynamics
• Demand Drivers
• Patch Manufacturing Dynamics
• Release Liners
• Backing Films
• Semi-permeable Membranes
• Adhesives
• Markets for Transdermal CNS Therapeutics
• ADHD
• Daytrana
• Methylphenidate (Daytrana - Noven)
• Alzheimer's Disease
• Rivastigmine (Exelon - Novartis)
• Aricept Transdermal - Recent Activity
• Exelon
• Depression
• Antidepressants
• Selegiline (EMSAM - Mylan)
• Nausea
• Alkaloids
• Scopolamine (Transderm Scop) GlaxoSmithKline Consumer Health
• Granisetron (Sancuso - ProStrakan)
• Parkinson's Disease
• Levodopa
• Rotigotine (Neupro - Schwarz/UCB))
• Schizophrenia
• Asenapine (Secuado - Noven)
• Transdermal CNS Drug Product Analysis and Market Assessments
• FDA Approved Transdermal CNS Prescription Products
• CNS Stimulants
• AChE Inhibitors
• Atypical Antipsychotics
• Alkaloids
• Dopamine Agonists
• 5-HT3 Receptor Antagonists
• MAO Inhibitors
• Strategic Factors and Branding Issues
• Dopamine Agonists
• Company Profiles